SPRY (ARS Pharmaceuticals, Inc.) Stock Market Reviews

crown

search

Read and share opinions on SPRY (ARS Pharmaceuticals, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock marke

SPRY

ARS Pharmaceuticals, Inc.

clarify Biotechnology

bookmark Healthcare

public United States

Sell Neutral Buy

Latest News

ARS Pharmaceuticals Inc (SPRY) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic ...
Nov 10, 2025
ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Beats Revenue Estimates
Nov 10, 2025
ARS Pharma Launches Get neffy® on Us for Patients with Severe Allergic Reactions to Improve Access to neffy (epinephrine nasal spray)
Nov 4, 2025
ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results
Nov 3, 2025
ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy® (epinephrine nasal spray)
Oct 8, 2025
ARS Pharmaceuticals Gets Up to $250 Million Loan to Back Neffy Commercialization
Sep 29, 2025
ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy®
Sep 29, 2025
neffy® (epinephrine nasal spray) Approved in Japan as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
Sep 19, 2025
ARS Pharmaceuticals, Inc. (SPRY): A Bull Case Theory
Sep 17, 2025

Reviews